Solange Peters, MD, PhD from the University of Lausanne, Lausanne, Switzerland discusses the current treatment landscape of advanced non-small cell lung cancer (NCSLC) at the annual meeting of European Lung Cancer Conference (ELCC) 2017 in Geneva, Switzerland. Dr Peters talks about the importance of genetic screening of patients which could lead to more informed treatment decisions. It is also extremely crucial for clinicians to ensure that patients worldwide have access to the latest diagnosis and treatment methods as without this, the advantages and cost of research to develop the treatment methods is not being exploited in its entirety.